Biotechnology - Asia-Pacific


Current filters:


Popular Filters

151 to 161 of 161 results

Actelion drops setipiprant, gets miglustat approval in Japan


Switzerland-based Actelion Ltd (SIX: ATLN) announced says that it will re-direct its development efforts…

ActelionAsia-PacificBiotechnologyBrazavesInflammatory diseasesMiglustatRare diseasesRegulationResearchsetipiprantZavesca

Kyowa Hakko sets up biosimilars joint venture with Fujifilm


Japanese digital camera and medical equipment conglomerate Fujifilm and drugmaker Kyowa Hakko Kirin have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyFujifilm Kyowa Kirin BiologicsGenericsHumiraKyowa Hakko KirinMergers & AcquisitionsResearch

Panacea Biotech inaugurates new cancer drug facility in India


Indian health care management company Panacea Biotec says that it has inaugurated a new state-of-the-art…

Asia-PacificBiotechnologyFinancialMarkets & MarketingPanacea Biotec

Pharming in deal with Hyupjin for Ruconest in South Korea


Dutch biotech firm Pharming Group (NYSE Euronext: PHARM) has entered into an agreement with Seoul-based…

Asia-PacificBiotechnologyHyupjin CorpLicensingPharmingRare diseasesRhucinRuconest

Anaphore buys Chinese firm RuiYi for GPCR biologics platform


Privately-held US company Anaphore says it has acquired Shanghai, China-based RuiYi, bringing the company…

AnaphoreAsia-PacificBiotechnologyMergers & AcquisitionsRuiYi

New IP legislation will encourage medical research in Australia, says trade group


New legislation overhauling the Australian patent system will encourage medical research and bring Australia…


Pfizer and Biocon cancel biosimilars deal


Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Apexigen licenses MAb to Gansu Duyiwei for China


Privately-held US biopharma firm Apexigen has entered into a collaboration to grant an exclusive license…

ApexigenAsia-PacificBiotechnologyGansu DuyiweiLicensingOncology

AusBiotech sets out stall on R&D tax incentive discussion paper


Australian trade group AusBiotech has lodged a submission in response to the “Discussion Paper:…


Immuron joins academia for C. Difficile therapeutics


Australian biotechnology firm Immuron (ASX: IMC) has entered into a collaboration agreement with Australia’s…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyImmuronResearch

151 to 161 of 161 results

Back to top